Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial

• المؤلفون الرئيسيون: Ozra TABATABAEI-MALAZY (مؤلف), Masumeh NORANI (مؤلف), Ramin HESHMAT (مؤلف), Mostafa QORBANI (مؤلف), Afsaneh VOSOOGH (مؤلف), Behnaz AFRASHTEH (مؤلف), Farzin KAHKESHAN (مؤلف), Arman AJAMI (مؤلف), Bagher LARIJANI (مؤلف)
• التنسيق: كتاب
• منشور في: Tehran University of Medical Sciences, 2018-08-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Background: Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of fractures as the main goal of treatment. We compared the efficacy and safety of a new biosimilar recombinant human parathyroid hormone (CinnoPar®, CinnaGen, Iran) to the reference product (Forteo®,...